M. Morrier
La Roche College
5 Papers
1 Citations
M. Morrier is an academic researcher from La Roche College. The author has contributed to research in topics: Medicine & Abacavir/Lamivudine. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Septic arthritis of the facet joint.
Vincent André,M. Pot-Vaucel,Céline Cozic,E. Visée,M. Morrier,Stéphane Varin,Grégoire Cormier +6 more
TL;DR: Assessing the facet joint is essential in case of inflammatory back pain, and the radiologist must be asked to perform this examination.
29
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, a new risk factor for cryptococcosis
J. Brochard,F. Morio,J. Mahe,P. Le Pape,Thomas Guimard,B Mahe,M. Leterrier,M. Morrier,François Raffi,David Boutoille +9 more
TL;DR: Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib, a Bruton's tyrosine kinase inhibitor, and warn patients of the risk of Cryptococcus neoformans infections.
12
Iconographies supplémentaires de l'article : Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)
Clotilde Allavena,C. Volteau,Elisabeth André-Garnier,Thomas Guimard,Nolwenn Hall,L. Khatchatourian,M. Morrier,Eric Billaud,Audrey Rodallec,V Reliquet,T. Jovelin,L. Le Guen,P. Perré,Matthieu Grégoire,François Raffi +14 more
- 24 Dec 2018
TL;DR: In this paper, the authors evaluated the pharmacokinetics, virologic outcomes, safety, and patient satisfaction of switching from stable abacavir/lamivudine and nevirapine to a single tablet of abacanavir, lambiclavir, and dolutegravir.
1
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Clotilde Allavena,C. Volteau,E. André-Garnier,Thomas Guimard,Nolwenn Hall,L. Khatchatourian,M. Morrier,Eric Billaud,A. Rodallec,V Reliquet,T. Jovelin,L. Le Guen,P. Perré,Matthieu Grégoire,François Raffi +14 more
TL;DR: The transient predator effect of nevirapine on dolutegravir had no clinical consequences after switching from ne virapine to doluteGravir, neither on safety nor maintenance of virologic suppression, and had no consequences on patient satisfaction.
1
Effet du décubitus ventral vigile chez des patients hospitalisés hors réanimation pour une pneumonie hypoxémiante à COVID-19 : un essai randomisé multicentrique
Mai-Anh Nay,R. Hindré,C. Perrin,J. Clement,Laurent Plantier,Aymeric Sève,S. Druelle,M. Morrier,Jarmo Laine,L. Colombain,Gaëlle Corvaisier,Nicolas Bizien,Xavier Pouget-Abadie,Audrey Bigot,S. Jamard,Elsa Nyamankolly,G. Fossat,Benjamin Planquette,Thierry Boulain +18 more
TL;DR: In this paper , the bénéfice du décubitus ventral vigile (DV) chez les patients oxygénodépendants hospitalisés hors réanimation for a pneumonie COVID-19 hypoxémiante was evaluated.